ALLMedicine™ Adrenocortical Carcinoma Center
Research & Reviews 654 results
https://doi.org/10.1186/s13256-021-03234-1 10.1177/1753465810386051 10.1016/S0022-3476(05)80296-3 10.1002/ijc.24679 10.1093/jnci/95.5.381 10.1093/jnci/djs481 10.1056/NEJM199502233320803 10.1038/bjc.1993.474 10.1016/j.jcf.2017.06.013 10.1007/s11894-017-0546-0 10.1016/j.jcf.2017.07.009 10.1016/j.jcf.2011.05.003 10.1016/S1470-2045(18)30188-8 10.1016/S2214-109X(19)30482-6 10.1053/j.gastro.2017.12.012 10.1016/j.ejogrb.2017.12.005 10.1097/IGC.0b013e318292da82 10.12659/MSM.899341 10.1136/thorax.56.8.649 10.3390/ijms21093133 10.1016/S1470-2045(18)30250-X 10.1001/archinternmed.2009.440 10.1002/jmri.27030 10.1542/peds.76.5.814 10.3892/or.2015.3829
Journal of Medical Case Reports; Appelt D, Fuchs T et. al.
Jan 20th, 2022 - Previous reports have shown an increased number of colorectal cancers in patients with cystic fibrosis. We assessed the database of our cystic fibrosis center to identify patients with all kinds of cancer retrospectively. All patients visiting the...
https://doi.org/10.1530/ERC-21-0202
Endocrine-related Cancer; Haberbosch L, Maurer L et. al.
Jan 12th, 2022 - Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis. Mitotane, a derivative of the pesticide DDT, has been used successfully as first line chemotherapy since the 1960s, if maintained within a narrow therapeutic wind...
https://doi.org/10.1245/s10434-021-11175-8
Annals of Surgical Oncology; Tseng J, DiPeri T et. al.
Jan 8th, 2022 - ASO Visual Abstract: Adrenocortical Carcinoma-The Value of Lymphadenectomy.|2022|Tseng J,DiPeri T,Chen Y,Shouhed D,Ben-Shlomo A,|
https://doi.org/10.1113/JP282690
The Journal of Physiology; Shalomov B, Handklo-Jamal R et. al.
Dec 28th, 2021 - G protein-gated, inwardly rectifying potassium channels (GIRK) mediate inhibitory transmission in brain and heart, and are present in the adrenal cortex. GIRK4 (KCNJ5) subunits are abundant in the heart and adrenal cortex. Multiple mutations of KC...
https://doi.org/10.1097/MD.0000000000027864
Medicine Chen Q, Ren Z et. al.
Dec 18th, 2021 - Adrenocortical carcinoma is an invasive malignancy with poor prognosis, high recurrence rate and limited therapeutic options. Therefore, it is necessary to establish an effective method to diagnose and evaluate the prognosis of patients, so as to ...
Guidelines 1 results
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.
Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...
Clinicaltrials.gov 16 results
https://clinicaltrials.gov/ct2/show/NCT00568139
Jul 13th, 2021 - Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many side effects are not well documented. Therefore, we are aiming at collecting data about side effects in patients treated with mitotane
https://clinicaltrials.gov/ct2/show/NCT00457587
Jun 7th, 2021 - Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of ...
https://clinicaltrials.gov/ct2/show/NCT00453674
Jun 4th, 2021 - Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of patients with adrenocortical cancer. The registration of as many patients as possible helps to collect data for the prognosis and prospects of success regard...
https://clinicaltrials.gov/ct2/show/NCT02673333
Apr 6th, 2021 - Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
https://clinicaltrials.gov/ct2/show/NCT03127774
Jan 28th, 2021 - Adrenocortical carcinoma (ACC) is a rare tumor with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months. The treatment of choice for a localized primary or recurrent tumor is surgical rese...
News 23 results
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer
Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...
https://www.medscape.com/viewarticle/959868
Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...
https://www.onclive.com/view/genetic-data-points-to-potential-new-therapeutic-target-for-adrenocortical-carcinoma
Dec 20th, 2020 - According to study results presented at the 21st Annual Congress of the American Association of Clinical Endocrinologists, overexpression of pituitary tumor transforming gene 1 (PTTG1) is associated with low survival rates in patients with adrenoc...
https://www.medscape.com/viewarticle/934790
Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...
https://reference.staging.medscape.com/viewarticle/904250
Nov 5th, 2018 - Clinical practice guidelines for the management of adrenocortical carcinoma in adults were released in October 2018 by the European Society of Endocrinology.[1] Diagnosis Perform a detailed hormonal workup of all patients with suspected adrenocort...
